Livesaving plasma

Plasma, the liquid part of blood, contains proteins and other components of incalculable therapeutic value. From this essential life fluid, Grifols develops medicines to treat patients around the world living with chronic and rare diseases that can be life-threatening.

We combine our vast knowledge and longstanding excellence in plasma with new technology platforms to accelerate the development of novel plasma and non-plasma treatments.

Patient Centricity

Focused on patients

The patients we serve around the world are able to lead better lives. Patients inspire the work we do every day.

Key treatment areas


  • Immunoglobulin (IgG) is indicated to treat primary and secondary immunodeficiencies, in which the immune system is diminished or impaired and the body does not have the ability to fight infections.
  • Specific hyperimmune immunoglobulins are used to provide immediate immune protection after exposure to possible infections such as rabies, tetanus, hepatitis A or hepatitis B, as well as to treat Rh incompatibility.


  • Albumin is used to restore circulatory volume and protein loss in pathophysiological conditions such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns. Its use as a treatment for decompensated liver cirrhosis with ascites, acute-on-chronic liver failure, hepatic encephalopathy and sepsis is currently under investigation.


  • Alpha-1 proteinase inhibitor is a plasma protein that prevents certain enzymes from attacking healthy lung tissue. It is used to treat alpha-1 antitrypsin deficiency, a genetic disease also known as alpha-1, which is a major cause of chronic obstructive pulmonary disease (COPD).


  • Factor VIII/von Willebrand factor and factor IX are clotting factors indicated in the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B, which are genetic deficiencies that prevent the blood from clotting properly.
  • Another plasma protein involved in the blood clotting process, antithrombin III, is indicated in the treatment of hereditary antithrombin deficiency. Research is also currently underway in COVID-19 and trauma.
  • Fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, is indicated in chronic immune thrombocytopenia, a disorder in which the immune system attacks and destroys platelets.
  • Immunoglobulin (IgG) is indicated to treat immune thrombocytopenia.
  • The combination of the plasma protein fibrinogen with the enzyme thrombin acts as a biological sealant in the control of surgical bleeding.


  • Immunoglobulin (IgG) is indicated for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare autoimmune neurological disease in which the immune system attacks and damages the protective coating covering the nerves, causing weakness, pain, numbness, and tingling in the arms and legs, as well as loss of balance that may impair the ability to walk.
  • Plasma exchange with albumin is being investigated for the treatment of Alzheimer's disease, the most common form of dementia.

Plasma at work


Grifols product portfolio

How can we help you?

Read more

See how we innovate


Dedicated to improving people’s lives

We develop, produce and market innovative medicines, solutions and services in more than 110 countries.

Read more